May 06, 2020
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
Apr 22, 2020
Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD
Apr 08, 2020
Trovagene to Present at the 19th Annual Needham Healthcare Conference
Apr 01, 2020
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
Feb 27, 2020
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
Feb 13, 2020
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
Jan 29, 2020
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
Jan 21, 2020
Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium
Dec 04, 2019
Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)
Nov 14, 2019
Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®
Nov 07, 2019
Trovagene Announces Third Quarter 2019 Results and Highlights
Nov 06, 2019
Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting
Oct 25, 2019
Trovagene Announces $5.0 Million Private Placement Priced At-the-Market
Oct 02, 2019
Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer (TNBC)
Oct 01, 2019
Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO
Sep 30, 2019
Positive Data from Trovagene Phase 1b/2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) Conference
Sep 19, 2019
Trovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2
Sep 03, 2019
Trovagene to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Aug 15, 2019
Trovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference
Jul 15, 2019
Trovagene Commences Non-Deal Investor Roadshow